Abstract
In order to provide reference for the prevention and treatment of CRBSI during clinical intravenous infusion therapy, this paper investigates the incidence of catheter-related bloodstream infection (CRBSI) in the treatment of midline catheters (MCs) and peripherally inserted central catheters (PICCs) by intravenous infusion. Web of Science, PubMed, Scopus, Embase, Cochrane Library, and ProQuest are searched to collect CRBSI-related studies on MC and PICC. The retrieval time is from the database construction to August 2020. Two researchers independently searched and screened literature quality evaluation and extracted data according to inclusion and exclusion criteria, and RevMan 5.3 software was used for analysis. Eleven studies are included, with a total of 33809 patients. The incidence of CRBSI in the MC group is 0.599% (43/7079), and that in the PICC group is 0.4993% (133/26630). Meta-analysis showed that the incidence of CRBSI in the MC group is higher than that in the PICC group (OR = 0.72, 95% CI = 0.43–1.08, P=0.11), and the difference is statistically significant when low-quality studies are excluded (OR = 0.60, 95% CI = 0.39–0.93, P=0.02). There is no significant difference in the incidence of CRBSI between MC group and PICC group (P > 0.05), American subgroup (OR = 0.52), and British subgroup (OR = 4.86), the results of the two groups are opposite, and the incidence of CRBSI between the MC group and PICC group is statistically significant. There is no significant difference in the incidence of CRBSI between the adult and other subgroups (all P > 0.05). There is no significant difference in the incidence of CRBSI between the MC group and the PICC group (P > 0.05). Overall, the inter-study stability is general, the quality is good and the medium is good, and there is no obvious publication bias. The risk of CRBSI in MC and PICC is systematically evaluated and meta-analyzed for the first time. The incidence of CRBSI in MC group is lower than that in PICC group during intravenous infusion therapy. Under the same conditions, MC patients can be given priority for intravenous infusion therapy. More high-quality and child-related studies are needed to further evaluate and explore the risk of CRBSI between MC and PICC.
Highlights
Catheter-related bloodstream infection (CRBSI) is a serious complication of intravenous fluid therapy, which is closely related to the length of hospital stay, cost, and prognosis of patients [1]
Due to the low attention paid to midline catheters (MCs) studies in the early stage and the increasing number of studies in recent years, there is no systematic evaluation of the incidence of CRBSI in MC and peripherally inserted central catheters (PICCs) intravenous infusion therapy. rough systematic review and meta-analysis, this study explored the difference in the incidence of CRBSI between MC and PICC intravenous infusion therapies, in order to provide reference for the prevention and treatment of CRBSI during clinical intravenous infusion therapy
Search terms are as follows: (1) midline catheter∗, midline venous catheter∗, midline peripheral catheter∗, medium-term intravenous access∗; (2) PE-ripherally inserted central catheter∗, percutaneous indwelling central catheter∗, peripherally inserted central Catheter∗, PICC line∗, PICC∗; (3) Bacteremia, bacteriemia, septicemia, sepsis, infection∗. e retrieval time is from the database construction to August 2020
Summary
Catheter-related bloodstream infection (CRBSI) is a serious complication of intravenous fluid therapy, which is closely related to the length of hospital stay, cost, and prognosis of patients [1]. CRBSI is defined as bacteremia or mycoemia with fever within 48 hours of catheter insertion or catheter removal (>38). E 2015 standard of nursing practice for intravenous infusion therapy of Infusion Nurses Society (INS) recommends that all drugs and fluids that can pass through peripheral superficial venous devices be used for medium-length catheters [8]. Due to the low attention paid to MC studies in the early stage and the increasing number of studies in recent years, there is no systematic evaluation of the incidence of CRBSI in MC and PICC intravenous infusion therapy. Due to the low attention paid to MC studies in the early stage and the increasing number of studies in recent years, there is no systematic evaluation of the incidence of CRBSI in MC and PICC intravenous infusion therapy. rough systematic review and meta-analysis, this study explored the difference in the incidence of CRBSI between MC and PICC intravenous infusion therapies, in order to provide reference for the prevention and treatment of CRBSI during clinical intravenous infusion therapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
